Medicare Enrolled
Dr. Alberto Parra, MD
Internal Medicine · Arlington, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Parra from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Parra?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Parra
Dr. Alberto Parra is an internal medicine specialist in Arlington, TX, with 15 years of NPI registration. Based on federal Medicare data, Dr. Parra performed 59,444 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Parra received a total of $28,569 from 72 pharmaceutical and/or device companies across 432 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Parra is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years of NPI registration
▲ Top 1% volume in TX
$28,569 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗59,444
Medicare services
Top 1% in TX for internal medicine
Not available
Unique patients (not deduplicated)
$23
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 19,800 | $42 | $115 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
14,700 | $0 | $5 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
14,250 | $1 | $3 |
| Bevacizumab biosimilar injection, 10 mg An injection of bevacizumab-awwb, a biosimilar medication, administered in a 10 mg dose. |
2,010 | $21 | $135 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,764 | $0 | $5 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,450 | $1 | $52 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
851 | $2 | $5 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
446 | $94 | $275 |
| Injection, triptorelin pamoate, 3.75 mg | 431 | $286 | $1,000 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
423 | $11 | $70 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
390 | $134 | $350 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
338 | $93 | $412 |
| COVID-19 test, self-administered An FDA-approved, authorized, or cleared test kit for nonprescription self-administered and self-collected use. This code represents the provision of one test count. |
316 | $12 | $30 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
256 | $7 | $300 |
| Principal care management for high-risk disease, first 30 minutes This service covers the initial 30 minutes of clinical staff time per calendar month to manage a single high-risk disease. It is directed by a healthcare professional. |
171 | $48 | $160 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
168 | $61 | $175 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
166 | $22 | $100 |
| Piflufolastat F-18 diagnostic injection A diagnostic injection of the radioactive tracer piflufolastat F-18 used for imaging. The dose specified is 1 millicurie. |
142 | $593 | $1,841 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
137 | $24 | $105 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
121 | $49 | $202 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
117 | $45 | $401 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
116 | $151 | $681 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
106 | $21 | $93 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
93 | $11 | $60 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
79 | $48 | $190 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
70 | $15 | $60 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
67 | $93 | $250 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
60 | $1 | $10 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
51 | $1,156 | $4,069 |
| Additional 30 minutes of principal care management This service covers each additional 30 minutes of clinical staff time directed by a healthcare professional for managing a single high-risk disease, billed per calendar month. |
45 | $37 | $120 |
| New patient office visit, complex (60-74 min) | 38 | $168 | $500 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
33 | $59 | $250 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 33 | $106 | $450 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
32 | $62 | $175 |
| Whole body bone and joint nuclear medicine scan A nuclear medicine imaging test that uses a radioactive tracer to create pictures of the entire skeleton and joints. This scan helps evaluate bone health and detect abnormalities throughout the body. |
30 | $177 | $804 |
| Technetium Tc-99m medronate diagnostic injection An injection of Technetium Tc-99m medronate used for diagnostic imaging studies. The dose administered is up to 30 millicuries per study. |
29 | $48 | $125 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
24 | $44 | $150 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
24 | $49 | $161 |
| CT scan of abdomen and pelvis, without contrast A computed tomography scan that creates detailed images of the abdominal and pelvic organs. The procedure is performed without the use of intravenous contrast dye. |
19 | $67 | $338 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
19 | $10 | $50 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
16 | $37 | $300 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
13 | $128 | $400 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
25.3% high complexity
71.7% medium
3.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$28,569
Total received (2018-2024)
Avg $4,081/year across 7 years
Top 4% in TX for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
72
Companies
432
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$18,600
2023
$3,115
2022
$966
2021
$383
2020
$792
2019
$2,486
2018
$2,226
Payments by company (2024)
EMD Serono, Inc.
$15,682
Janssen Biotech, Inc.
$574
Merck Sharp & Dohme LLC
$254
AstraZeneca Pharmaceuticals LP
$203
Novartis Pharmaceuticals Corporation
$189
Gilead Sciences, Inc.
$186
Daiichi Sankyo Inc.
$180
PFIZER INC.
$154
Johnson & Johnson Health Care Systems Inc.
$141
Blueprint Medicines Corporation
$140
Regeneron Healthcare Solutions, Inc.
$134
ABBVIE INC.
$94
Astellas Pharma US Inc
$92
Incyte Corporation
$71
Eisai Inc.
$68
E.R. Squibb & Sons, L.L.C.
$66
Celgene Corporation
$65
Genmab U.S., Inc.
$51
ARRAY BIOPHARMA INC
$44
Dendreon Pharmaceuticals LLC
$31
SERVIER PHARMACEUTICALS LLC
$25
Tempus AI, Inc
$24
GlaxoSmithKline, LLC.
$23
Boehringer Ingelheim Pharmaceuticals, Inc.
$22
Stemline Therapeutics Inc.
$20
Kite Pharma, Inc.
$19
SOBI, INC
$18
Aveo Pharmaceuticals, Inc.
$17
Immunocore Limited
$16
Top 3 companies account for 88.8% of 2024 payments
All-time payments by company (2018-2024) ›
EMD Serono, Inc.
$16,587
Janssen Biotech, Inc.
$2,077
Astellas Pharma US Inc
$848
Daiichi Sankyo Inc.
$844
PFIZER INC.
$584
Merck Sharp & Dohme Corporation
$479
Novartis Pharmaceuticals Corporation
$448
AstraZeneca Pharmaceuticals LP
$385
Puma Biotechnology, Inc.
$374
Sirtex Medical Inc
$359
Amgen Inc.
$352
E.R. Squibb & Sons, L.L.C.
$314
Celgene Corporation
$296
Merck Sharp & Dohme LLC
$291
Gilead Sciences, Inc.
$278
Janssen Scientific Affairs, LLC
$247
Clovis Oncology, Inc.
$210
Ipsen Biopharmaceuticals, Inc
$200
Dendreon Pharmaceuticals LLC
$186
Exelixis Inc.
$174
Eisai Inc.
$159
Verastem, Inc.
$158
AbbVie, Inc.
$157
Incyte Corporation
$152
Takeda Pharmaceuticals U.S.A., Inc.
$151
Johnson & Johnson Health Care Systems Inc.
$141
Blueprint Medicines Corporation
$140
PUMA BIOTECHNOLOGY, INC.
$136
Regeneron Healthcare Solutions, Inc.
$134
Genentech USA, Inc.
$125
Bayer Healthcare Pharmaceuticals Inc.
$120
ABBVIE INC.
$119
Teva Pharmaceuticals USA, Inc.
$92
Seattle Genetics, Inc.
$89
GlaxoSmithKline, LLC.
$69
ARRAY BIOPHARMA INC
$68
GENZYME CORPORATION
$68
Seagen Inc.
$67
Lilly USA, LLC
$66
Foundation Medicine, Inc.
$53
Genmab U.S., Inc.
$51
TG THERAPEUTICS, INC.
$50
TESARO, Inc.
$46
Rigel Pharmaceuticals, Inc.
$42
Novocure Inc.
$41
EISAI INC.
$32
Pharmacyclics LLC, An AbbVie Company
$31
BeiGene USA, Inc.
$26
SERVIER PHARMACEUTICALS LLC
$25
Tempus AI, Inc
$24
Sun Pharmaceutical Industries Inc.
$24
Coherus Biosciences Inc.
$23
Helsinn Therapeutics (U.S.), Inc.
$23
Acrotech Biopharma Inc.
$23
Boehringer Ingelheim Pharmaceuticals, Inc.
$22
Bayer HealthCare Pharmaceuticals Inc.
$22
Heron Therapeutics, Inc.
$21
Tactile Systems Technology Inc
$20
Stemline Therapeutics Inc.
$20
Karyopharm Therapeutics Inc.
$19
Taiho Oncology, Inc.
$19
Kite Pharma, Inc.
$19
SOBI, INC
$18
Aveo Pharmaceuticals, Inc.
$17
Immunocore Limited
$16
MENARINI SILICON BIOSYSTEMS, INC.
$15
Mylan Institutional Inc.
$14
Epizyme, Inc.,
$14
Dova Pharmaceuticals
$14
TerSera Therapeutics LLC
$14
Acrotech Biopharma LLC
$14
Array BioPharma Inc.
$11
Top 3 companies account for 68.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · AYVAKIT · Abraxane · Alecensa · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BENDEKA · BOSULIF · BRUKINSA · Balversa · Bavencio · Braftovi · CALQUENCE · CARVYKTI · CHANTIX · CINVANTI · CYRAMZA · Cabometyx · Cellsearch · Copiktra · DARZALEX · DAURISMO · DOPTELET · Doptelet · ELIQUIS · ENHERTU · ERBITUX · ERLEADA · Enhertu · Erleada · FOTIVDA · Flexitouch Plus · Fulphila · GAZYVA · GILOTRIF · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INFUGEM · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lupron · MEKINIST · MONJUVI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · Oncology · Onivyde · Optune · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Padcev · Pomalyst · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rubraca · SANDOSTATIN · SIR-Spheres Microspheres · SOMATULINE DEPOT · STELARA · SUTENT · Stivarga · TASIGNA · TAXOTERE · TAZVERIK · TUKYSA · Tavalisse · Tivdak · Trodelvy · UKONIQ · Udenyca · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XPOVIO · XTANDI · Xtandi · Yescarta · ZEJULA · ZOLADEX · ZYKADIA · ZYTIGA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
2,065
County median income
$81,905
Nearest hospital to ZIP centroid (approximate)
MEDICAL CITY ARLINGTON
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Parra is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Parra experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Parra performed 19,800 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Parra receive payments from pharmaceutical companies?
Yes. Dr. Parra received a total of $28,569 from 72 companies across 432 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Parra's costs compare to other internal medicine physicians in Arlington?
Dr. Parra's average Medicare payment per service is $23. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Parra) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Arlington
Browse internal medicine physicians in Arlington ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in TX
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in TX
Which TX internal medicine physicians receive the most from drug and device companies.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology